Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA

Executive Summary

An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings
Advertisement

Related Content

EOP2A Guidance Allows That Resource Constraints Might Block Meetings
Priority Review's Luster Dims In "Safety First Era" But Retains Value - Parexel
Priority Review's Luster Dims In "Safety First Era" But Retains Value - Parexel
Lessons Learned: New FDA Guidance On Meetings With Sponsors Adds Depth
Lessons Learned: New FDA Guidance On Meetings With Sponsors Adds Depth
FDA Puts Dose Selection At Top Of Agenda For End-Of-Phase 2A Meetings
Complete Submissions Are Key To Good Review Management Principles – FDA
First Cycle Approval Rate Tops 50% For 2006 NMEs; Merck Hits 100%
FDA Noxafil Approval Delayed By Last-Minute Label, Data Integrity Issues
Drugs With Better Sales Have Better Development Times, Study Finds
Advertisement
UsernamePublicRestriction

Register

PS046861

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel